The potential of triplet combination therapies for patients with FLT3-ITD-mutated acute myeloid leukemia

A Bruzzese, E Vigna, EA Martino… - Expert Review of …, 2024‏ - Taylor & Francis
Introduction Acute myeloid leukemia (AML) encompasses a heterogeneous group of
aggressive myeloid malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are …

Genetic, phenotypic, and clinical heterogeneity of NPM1-mutant acute myeloid leukemias

U Testa, E Pelosi, G Castelli - Biomedicines, 2023‏ - mdpi.com
The current classification of acute myeloid leukemia (AML) relies largely on genomic
alterations. AML with mutated nucleophosmin 1 (NPM1-mut) is the largest of the genetically …

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1‐mutated AML

E Smith, EG Atenafu, A Bankar, S Chan… - European Journal of …, 2024‏ - Wiley Online Library
Abstract Nucleophosmin‐1 (NPM1)‐mutated AML is a molecularly defined subtype typically
associated with favorable treatment response and prognosis; however, its prognostic …